ZÖZübeyde Nur Özkurt

Zübeyde Nur Özkurt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zübeyde Nur Özkurt has a total of 232 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Real-world outcomes for primary and secondary central nervous system lymphoma

    by Başak Bostankolu Değirmenci, Zübeyde Nur Özkurt, Zeynep Arzu Yeğin, Abdullah Münci Yağcı

    Aims: Central nervous system lymphoma (CNSL) is a rare and aggressive subtype of extranodal non-Hodgkin lymphoma, including primary and secondary forms. Despite advances in treatment, outcomes remain suboptimal. In this study, real-world treatment outcomes and prognostic factors in CNSL patients were evaluated. Methods: The study should be described, including selection criteria, design (randomized, retrospective/prospective, etc.), and statistical methods applied, if applicable. Results: The median age was 53 years, and 62.5% of patients had primary CNSL. High-dose methotrexate-based regimens yielded high response rates, with overall response rates of 92.3% for the MATRix regimen and 86.7% for the modified Bonn protocol. Autologous stem cell transplantation (ASCT) was associated with an improvement in complete/unconfirmed complete response rates (52.5% pre-ASCT vs. 65% post-ASCT). At a median follow-up of 1124 days, the overall survival and progression-free survival rates were 52.5% and 35%, respectively. Relapse occurred in 50% of patients. Prognostic scoring systems demonstrated limited applicability due to missing data and the small sample size. Conclusion: High-dose methotrexate-based regimens followed by ASCT remain effective in CNSL; however, relapse rates remain high. Improved prognostic models and novel therapies are needed.

  • Open Access

    Bronchiolitis Obliterans Syndrome After Allogeneic HSCT: Clinical Characteristics and Survival Outcomes in a Single Center Cohort

    by Emine Merve Savaş, Nurdan Kokturk, Ahmet Alparslan Ceran, Şeyma Yıldız, Münevver İrem Kök Yılmaz, Başak Bostankolu Değirmenci, Zeynep Arzu Yeğin, Gonca Erbaş, Özlem Güzel Tunçcan, Aysun Sarıer, et al.

    Background/Objectives: Chronic graft-versus-host disease (cGVHD) remains a significant complication after allogeneic stem cell transplantation. Bronchiolitis obliterans syndrome (BOS), the best characterized form of pulmonary cGVHD, represents its most severe and therapeutically challenging manifestation and is associated with poor long-term outcomes. However, data on treatment responses and survival remain limited. Methods: We performed a retrospective, single-center study to characterize the clinical features, treatment responses, and survival outcomes of patients with BOS following allo-HSCT. Results: Between January 2003 and December 2023, 28 (4.1%) of 678 transplanted patients met the National Institutes of Health (NIH) diagnostic criteria for BOS with lung scores of 2–3. The median age was 26 years (21–51), and 67.9% were male. The median time from transplantation to BOS diagnosis was 20.9 months (11.2–45.9). Median forced expiratory volume in one second (FEV1) declined from 97.5% at transplantation to 47.5% at BOS diagnosis, while median diffusing capacity for carbon monoxide (DLCO) decreased from 72% to 35% of predicted.The best observed response was partial response (PR). The overall first-line steroid-based response rate was 14.3%. In second- and subsequent-line settings, PR rates were 25% with ibrutinib, 25% with extracorporeal photopheresis, 33.3% with ruxolitinib, and 20% with mesenchymal stem cell therapy, while no responses were observed with imatinib. Median overall survival from transplantation was 90.9 months (48.4–133.5), whereas median survival from BOS diagnosis was 27.2 months (17.4–156.9). Survival after BOS diagnosis was significantly longer in patients with a prior history of acute GVHD (79.7 vs. 25.7 months; p = 0.026) and in those with concomitant extrapulmonary cGVHD compared with isolated BOS (79.7 vs. 7.6 months; p = 0.001). Conclusions: Treatment responses in stage 2–3 BOS were limited, and survival remained very poor, highlighting the importance of earlier recognition and more effective therapies before fibrotic progression.

  • Endocrine Complications in Long-Term Survivors of Allogeneic Hematopoietic Stem Cell Transplantation: Prevalence and Risk Factors

    by Burcu Aslan Candir, Elif Suyani, Zeynep Arzu Yegin, Zubeyde Nur Ozkurt, Merve Pamukcuoglu, Zeynep Sahika Aki, Gulsan Turkoz Sucak

    Amaç: Allojenik hematopoietik kök hücre nakli (AKHN), çeşitli hematolojik hastalıklar için potansiyel olarak küratif bir tedavi seçeneğidir. Ancak uzun dönem sağ kalan hastalar, yaşam kalitesini belirgin şekilde bozabilen geç başlangıçlı komplikasyonlardan, özellikle endokrin disfonksiyonlardan, giderek daha fazla etkilenmektedir. Bu çalışmanın amacı, AKHN sonrası en az bir yıl hastalıksız sağ kalan hastalarda geç dönem endokrin komplikasyonların sıklığını ve risk faktörlerini belirlemektir. Gereç ve Yöntemler: Tek bir üçüncü basamak merkezde AKHN uygulanmış 79 hastayı içeren retrospektif bir kohort analizi yapıldı. Nakil sonrası ilk yıl içinde hastalık nüksü gelişen ve kaybedilen hastalar çalışmaya dahil edilmedi. Demografik ve nakille ilişkili özellikler, graft-versus-host hastalığı, immünsüpresif tedaviler ve endokrin sonuçlara ait veriler analiz edildi. Nakil öncesinde ilgili endokrin hastalığı bulunan hastalar, ilgili endokrin komplikasyon gelişim risk analizlerinden dışlandı. Risk faktörleri tek değişkenli istatistiksel yöntemlerle değerlendirildi. Bulgular: Medyan takip süresi 38 aydı. Yeni gelişen endokrin komplikasyonlar hastaların önemli bir kısmında saptandı: dislipidemi (%77.3), osteopeni/osteoporoz (%58.2), hipogonadizm (%27.8), tiroid disfonksiyonu (hipotiroidi veya hipertiroidi: %36.2) ve hipertansiyon (%33.5). Anlamlı risk faktörleri arasında kadın cinsiyet, kortikosteroid maruziyeti, kısa süreli siklosporin kullanımı ve akut graft-versus-host hastalığı yer aldı. Avasküler nekroz %13.9 oranında saptandı ve bifosfonat, mikofenolat mofetil ve steroid kullanımı ile ilişkili bulundu. Sonuç: Endokrin komplikasyonlar, uzun dönem AKHN sağ kalanlarında oldukça yaygındır. Özellikle belirli risk faktörlerine sahip hastalarda düzenli ve kapsamlı endokrin izlem büyük önem taşımaktadır. Bu komplikasyonların erken tanınması ve yönetimi, bu hasta grubunda yaşam kalitesini artırabilir.

  • Open Access

    Peritransplantation Acute Kidney Injury Has a Considerable Impact on Early Complications and Prognosis in Allogeneic Hematopoietic Stem Cell Transplantation Recipients

    by Şeyma Yıldız, Emine Merve Savaş, Fatma Pınar Cihan, İlayda Aydın, Münevver İrEm Kök, Zübeyde Nur Özkurt, Zeynep Arzu Yeğin

    Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a curative treatment modality for a variety of hematological disorders. As baseline renal function is considered to have an essential role in the course of alloHSCT, it has been incorporated into pretransplantation scoring systems such as Sorror’s comorbidity index. The objective of this study was to assess the predictive factors that may influence the development of posttransplantation acute kidney injury (AKI), in accordance with the evaluation of the potential impact of AKI on transplantation outcome. Medical records of 434 alloHSCT recipients (median age: 44 [18–72] years; male/female: 259/175) were retrospectively reviewed. AKI was observed in a total of 316 patients (72.8%) in the first 100 days after alloHSCT. BK virus‐associated cystitis (HR: 0.412, 95% CI: 0.193–0.882; p = 0.022), sepsis (HR: 2.329, 95% CI: 1.251–4.337; p = 0.008), and infused CD34 + cell count (HR: 1.698, 95% CI: 1.186–2.430; p = 0.004) were identified as independent predictive factors for the development of posttransplantation AKI. The probability of overall survival (OS) was substantially higher in Stage I AKI compared to Stage II/III ( p = 0.03). Patients who had a higher eGFR on Day +30 had improved survival rates ( p = 0.005). AKI may represent a frequent cause of morbidity in the early posttransplantation course. Considering its multifactorial etiology, management of potential predisposing issues may help to prevent associated complications and improve transplantation outcomes.

  • Open Access

    Etiological Agents of Bacteremia in Patients with Hematological Malignancies: Evaluation of 18 Years of Data

    by Özge Özgen-Top, Pınar Aysert-Yıldız, Fatma Güçlü, Zübeyde Nur Özkurt, Zeynep Arzu Yeğin, Abdullah Münci Yağcı, Özlem Güzel-Tunçcan

    Objective: Timely initiation of effective empirical antibacterial therapy depends on continuous surveillance of local epidemiology and antimicrobial resistance patterns. This study aimed to evaluate the microbial etiology and antimicrobial susceptibility patterns of bacteremia in patients with hematological malignancies. Materials and Methods: This descriptive study was conducted in a university hospital between 2006 and 2023. We analyzed the distribution of microorganisms causing bacteremia and their antimicrobial susceptibility patterns in patients with hematological malignancies. Data were evaluated in two periods: 2006–2014 and 2015–2023. Results: A total of 2930 bacteremia episodes were recorded. Gram-positive organisms accounted for 60.5%, Gram-negative organisms for 32.3%, and yeasts for 4.0%. The most common Gram-positive pathogens were coagulase-negative staphylococci (CoNS), Enterococcus spp., and Streptococcus spp., while Escherichia coli, Klebsiella spp., and Acinetobacter baumannii predominated among Gram-negative organisms. A significant decrease in Gram-positive infections was observed in the second period (64.4% vs. 58.7%, p=0.007). Yeast infections increased significantly (2.9% vs. 5.9%, p<0.001), and Gram-negative infections showed a slight but non-significant rise (32.6% vs. 35.3%, p=0.244). Methicillin susceptibility among CoNS and Staphylococcus aureus was 33.9% and 61.7%, respectively. Resistance patterns among Gram-positive organisms remained relatively stable across periods, except for a notable decline in methicillin susceptibility in CoNS. Third-generation cephalosporin susceptibility was 58.1% for E. coli and 59.3% for Klebsiella spp. Meropenem susceptibility was below 90% for Klebsiella and Enterobacter spp. Resistance to piperacillin-tazobactam and meropenem among Enterobacteriaceae showed an upward trend in the second period. Conclusion: This 18-year surveillance study demonstrates changing microbiology and resistance patterns of bacteremia in patients with hematological malignancies. Gram-positive organisms, particularly CoNS, remain the most common pathogens, although their incidence is declining. Yeast infections are on the rise, and increasing resistance among Gram-negative organisms, especially to fluoroquinolones, piperacillin-tazobactam, and carbapenems, is concerning. Continuous local surveillance is essential for optimizing empirical treatment strategies and improving patient outcomes.


  • Open Access

    Clinical Manifestations, Treatment Characteristics and Clinical Outcome in Patients with Acquired Thrombotic Thrombocytopenic Purpura (aTTP) in the Real-World Setting: An Interim Analysis of the Turkish aTTP Registry

    by Sema Karakuş, Şule Mine Bakanay, Sevgi Kalayoğlu Beşişik, Ahmet Emre Eşkazan, Orhan Ayyıldız, Emel Gürkan, Ozan Salim, Volkan Karakuş, Nil Güler, Muzaffer Keklik, et al.

    This study aimed to investigate the clinical manifestations, treatment patterns and clinical outcomes in patients with iTTP across Türkiye via an interim analysis of the Turkish iTTP registry. A total of 215 patients with iTTP (median age at diagnosis 41 years, 58.6% female) diagnosed between 2001 and 2023 were retrospectively analyzed in the interim analysis of the prospective noninterventional observational multicenter iTTP registry study conducted at 19 tertiary hematology centers. Data on patient demographics, disease characteristics on initial admission, treatment characteristics, and responses, exacerbations/relapses, and the survival outcome were registered via electronic case report forms. Infection (15.0%), new drug initiation (9.7%), and pregnancy/postpartum (6.3%) within 3 weeks before diagnosis were the most prevalent potential triggers. Patients presented more commonly with systemic/constitutional (fatigue 68.8%; fever 18.1%) and neurologic (headache 40.0%, vertigo 32.1%), followed by hemorrhagic, gastrointestinal, renal, and cardiovascular manifestations. Based on the PLASMIC risk scoring, 77.8% of patients were initially at high risk for TTP. The initial treatment was commenced within the first 48 hours of hospital admission in 64.1% of patients (36.2% on the day of admission). Treatment was mainly based on TPE exchange (92.1%) and steroids (63.7%), while rituximab was used in 15.8% of patients. The clinical response rate was 79.9%, and clinical remission was achieved in 68.2% of patients. As for the ADAMTS13 levels, partial and complete responses were achieved in 17.7% and 14.6%, respectively. During a median of 30 months (range, 0.1 to 262.4 months) follow-up, 35 patients experienced exacerbations/relapses. Mortality occurred in 11 (5.5%) patients and was found to be disease-related in 6 (3.0%). This interim analysis of the nationwide Turkish iTTP registry study provided valuable data on the real-world clinical practice in the diagnosis and management of iTTP at different hematology clinics across the country.


  • Is Consolidation Therapy Effective in Multiple Myeloma Patients after High-Dose Chemotherapy and Autologous Stem Cell Transplantation: Single Center Real-Life Data with Cyclophosphamide-Bortezomib-Dexamethasone or Bortezomib-Lenalidomide-Dexamethasone?

    by Şeyma Yıldız, Asil Demirezen, Zeynep Arzu Yeğin, Münci Yağcı, Zübeyde Nur Özkurt

    Background An induction regimen, followed by autologous stem cell transplantation (ASCT) and subsequent maintenance therapy, is a standard practice for patients with newly diagnosed multiple myeloma (MM) who are eligible for transplantation. The effectiveness of short-term consolidation regimens following ASCT remains ambiguous and is not yet incorporated into MM guidelines. Methods This study consecutively enrolled patients with MM who had a bortezomib-based induction regimen prior to ASCT. A total of one hundred twelve patients who achieved at least a partial response at two months post-autologous stem cell transplantation were studied [median age: 59 (30–74) years; male/female ratio: 60/52]. Results Twenty-five patients did not undergo any consolidation, whereas eighty-seven patients got a median of 2 cycles (range: 1–6) of cyclophosphamide-bortezomib-dexamethasone (CyBorD) for Bortezomib-Lenalidomide-Dexamethasone (VRD) consolidation following ASCT. Progression-free survival (PFS) in the overall trial cohort was longer in patients receiving consolidation therapy (57 months versus 44 months, p = 0.06). Among patients exhibiting a very good partial response (VGPR) or partial response (PR) to ASCT, PFS was markedly prolonged in those who underwent consolidation cycles compared to those who did not (57 vs. 12 months; p = 0.04). Conversely, in the stringent complete remission (sCR) or complete remission (CR) cohort, PFS did not differ between patients who received consolidation cycles and those who did not. The analysis revealed no statistically significant differences in overall survival (OS) between the two answer category groups (p > 0.05). The PFS (p > 0.05) and incidence of severe toxicity (p > 0.05) were comparable for patients receiving CyBorD and VRD consolidation regimens. Conclusions Our study demonstrated that consolidation therapy is safe regarding its adverse effect profile, and that its beneficial impact on PFS in first-line treatment is particularly evident in patients exhibiting VGPR and PR to ASCT.

  • Day + 100 bone marrow megakaryocyte count predicts transplant outcome in patients with high-risk myelodysplastic syndrome and acute leukemia

    by Zeynep Arzu Yegin, Şeyma Yıldız, Emine Merve Savaş, Ali Şeker, Pınar Uyar Göçün, Zübeyde Nur Özkurt, Nalan Akyürek, Münci Yağcı

    Megakaryocytes (MKs), the precursor cells of platelets, have essential roles in a variety of pathophysiological processes in the bone marrow (BM) niche. Megakaryocytes maintain hematopoietic stem cell microenvironment through inflammatory and immunological responses. The primary objective of this research was to investigate the clinical impact of BM-MK counts in high-risk myelodysplastic syndrome and acute leukemia patients who underwent allogeneic hematopoietic stem cell transplantation (alloHSCT). Three hundred and forty-six patients (median age, 42 (15–71) years; male/female, 207/139) participated in the study. Based on the BM-MK counts on day + 100 of alloHSCT, the study population was classified into normal/high-MK+100 and low-MK+100 groups. The probabilities of progression-free survival (PFS) and overall survival (OS) were significantly better in the normal/high-MK+100 group (p < 0.001, p < 0.001). Nonrelapse mortality was found to be reduced in the same group of patients (p = 0.012). BM-MK+100 count, which was indicated to be a predictor for relapse after alloHSCT (p = 0.018), represented a considerable impact on PFS and OS (p = 0.017, p = 0.009). Megakaryocytes have regulatory roles in association with a comprehensive cytokine network in the BM microenvironment. Although the localization of MKs may be determinative for their spectrum of efficacy, distinct biological subgroups may also help to clarify the heterogeneity of their functional features. Prospective efforts in larger populations are required to illuminate the potential prognostic role of MKs in alloHSCT recipients.

  • Treatment Outcomes of Elderly Patients with Mantle Cell Lymphoma: A Multi-center Real-World Data

    by Ebru Kilic Gunes, Filiz Yavasoglu, Selin Kucukyurt, Fatma Aykas, Sureyya Yigit Kaya, Munevver Irem Kok Yilmaz, Murat Yildirim, Neslihan Andic, Ahmet Kursad Gunes, Volkan Karakus, et al.

    Mantle Cell Lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma (NHL), accounting for 5–7% of all lymphomas. Currently, there is no standardized treatment option for older patients (> 65 years), and optimizing MCL treatment in this group remains a significant clinical challenge. In this multicenter retrospective study, we aimed to evaluate the outcomes of first-line treatments, overall survival (OS), progression-free survival (PFS), and factors influencing survival in patients aged 65 years and older diagnosed with MCL. Patients aged ≥ 65 years diagnosed with MCL between November 2016 and January 2024 in six centers were included in this study. A total of 77 patients were included in the study, with 60 males (77.9%) and 17 females (22.1%). The median age was 71 years (range: 65–89). At diagnosis, 96.1% of patients had Stage III-IV disease, and 36.4% had an ECOG performance score of 2–3. Based on the MIPI-c score, 48% of patients had high-risk disease. As induction chemotherapy, 44.2% received R-CHOP, 13% received RB, 13% received R-CVP, and 29.8% received alternating R-CHOP/R-DHA-platinum. Additionally, 19.5% of patients underwent ASCT, and 28.6% received Rituximab maintenance after induction therapy or ASCT. The overall response rate (ORR) was 71.4%. After a median follow-up of 32 months, the median PFS was 18 months, and the median OS was 42 months. In multivariate analysis, independent risk factors for inferior PFS were LDH > ULN (HR: 2.09, 95% CI: 1.05–4.16, p = 0.035), Ki67 ≥ 30% (HR: 2.90, 95% CI: 1.38–6.10, p = 0.005), blastoid variant (HR: 1.86, 95% CI: 1.09–5.12, p = 0.040), and maintenance treatment (HR: 0.31, 95% CI: 0.12–0.75, p = 0.010). Independent risk factors for inferior OS were the maintenance treatment (HR: 0.29, 95% CI: 0.09–0.94, p = 0.040) and POD24 (HR: 2.04, 95% CI: 1.06–4.19, p = 0.044). There remains no universally accepted standard treatment for older MCL patients, and the disease remains incurable with current treatment modalities. However, advancements in targeted therapies and the optimization of maintenance strategies hold promise for improving survival in older and unfit patients. Future studies focusing on incorporating targeted therapies into first-line treatment and identifying high-risk factors that influence survival will be crucial in tailoring effective and individualized treatment approaches for this population.